BCMA CAR T-cell therapy recipients with CRS and ICANS. CRS grade 1 and 2 were 60% and 20%, respectively. No grade 3 to 4 CRS was observed. ICANS grade 1 and 3 were 20% and 10%, respectively, all of which reversed. No grade 4 ICANS was observed.